tirzepatide fda approval for weight loss Day 4: Zepbound (Tirzepatide – indication) Approved: November 2023 weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management Diabetes Drug - Tirzepatide Gets

The dual agonist nature of tirzepatide, acting on both GIP and GLP-1 receptors, contributes to its efficacy in glycaemic control and weight management but also influences the gastrointestinal side effect profile

Mounjaro and Zepbound can stay at room temperature for up to 21 days , as long as the temperature never exceeds 86 degrees Fahrenheit (30 degrees Celsius)

It is meant for single-use applications

If you can comfortably hold for three to five minutes, do it

Not for All Patients Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)